Akron Biotech, a Leading Global Supplier for the Cell Therapy Industry, Receives ISO 9001:2008 Certification

BOCA RATON, Fla.--(BUSINESS WIRE)--Akron Biotechnology, LLC’s Quality Management System was registered on November 30th, 2012 on the requirements of ISO 9001:2008 standards by BSI Group America Inc. This ISO Certification emphasizes Akron Biotech’s commitment to quality and meeting their customers’ needs and expectations. It covers all relevant functions of the Company: development, production, storage and distribution of Akron Biotech’s products, i.e. cryopreservation media, recombinant proteins, media supplements, scaffolds and cell culture systems.

“This is an important step in our commitment to quality standards that will continue to enhance our products and services. We are looking forward to building upon this base towards a stronger foundation of excellence and compliance as we develop innovative products within our pipeline.”

"This is an important step in our commitment to quality standards that will continue to enhance our products and services. We are looking forward to building upon this base towards a stronger foundation of excellence and compliance as we develop innovative products within our pipeline." said Claudia Zylberberg, PhD, Akron’s President and CEO. She further stated “We are committed to providing our customers with the unique ability to seamlessly transition from R&D to pre-clinical and clinical development with minimal change control in order for them to focus on their clinical outcome.”

About ISO 9001:2008 - Quality Management System

ISO 9001:2008 is one of the most widely used management systems related to quality standards and ensuring that a company is meeting the needs of customers and regulatory requirements. Third party certification bodies (e.g. BSI Group America, Inc) provide independent confirmation that an organization has met the requirements of ISO 9001:2008.

About Akron Biotech

As a global supplier, Akron Biotech (www.akronbiotech.com) manufactures and distributes components and raw materials for cell therapy discovery, development and commercialization, meeting the industry’s needs worldwide. The Company’s unique business model emphasizes flexibility, quality and unparalleled service from research and development through clinical trial to market authorization and commercial product.